United States · FDA National Drug Code directory

Exjade

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference: 0078-0469_17c39217-5502-420d-8d2e-799626756189
Product NDC: 0078-0469
Form: TABLET, FOR SUSPENSION
Composition / generic term: deferasirox
Labeler: Novartis Pharmaceuticals Corporation
Marketing category: NDA
Marketing start / end (source format): 20051130
Source listing expiry: 20271231

Source-listed ingredients

DEFERASIROX — 250 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0469-15) · 0078-0469-15

Source and coverage

Open FDA National Drug Code directory →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →